tZERO Group, Inc. filed a Form 425 on November 2, 2026, pursuant to Rule 425 under the Securities Act of 1933, disclosing an investor presentation related to a proposed business combination with FG Imperii Acquisition Corp. (Commission File No. 001-43056).
Jeffrey E. Eberwein, Chief Executive Officer and Director of Star Equity Holdings, Inc., filed a Form 4 on November 2, 2026, disclosing the sale of 2 shares of Series A Preferred Stock on October 29, 2026, under a Rule 10b5-1 trading plan.
On November 2, 2026, tZERO Group, Inc. filed a Form 425 announcing a definitive business combination agreement with FG Imperii Acquisition Corp. (NASDAQ:FGII), a special purpose acquisition company, through which tZERO expects to become a publicly traded company.
tZERO Group, Inc. filed a Form 425 on November 2, 2026, disclosing a planned business combination with FG Imperii Acquisition Corp. that would value tZERO at $350 million and list the combined company on NYSE American under the ticker TZRO.
John W. Gamble Jr., Executive Vice President, CFO and COO of Equifax Inc., filed a Form 4 on November 2, 2026, reporting the sale of 4,000 shares of Equifax common stock on October 29, 2026.
Harald Schneider, EVP and Chief D&A Officer of Equifax Inc, filed a Form 4 on November 2, 2026, reporting a disposition of 689 shares of Equifax common stock on October 30, 2026, via transaction code F at a price of $184.60 per share.
A statement of changes in beneficial ownership was filed on November 2, 2026, disclosing that John Paulson, a director of Bausch & Lomb Corp (NYSE:BLCO), acquired 1,125 restricted share units on October 29, 2026.
Olivier Bron, CEO of Bloomingdale's and an officer of Macy's, Inc. (NYSE:M), filed a Form 4 on November 2, 2026, reporting the vesting of restricted stock units and related tax-withholding share disposals on November 1-2, 2026.
Director Lainie Goldstein filed a Form 4 with the SEC on November 2, 2026, reporting the acquisition of 502 deferred stock units in Phreesia, Inc. (NYSE:PHR) on October 30, 2026, under the company's Non-Employee Director Deferred Compensation Program.
Jeffrey Bertolini, Chief Operating Officer of Carlsmed, Inc. (NASDAQ:CARL), filed a Form 4 on November 2, 2026, reporting the exercise of a stock option and sale of 243 shares of common stock on October 30, 2026, pursuant to a Rule 10b5-1 trading plan.